Insights

Following the Government's publication of the 10 year Industrial Strategy, it has now published its sector plans for its eight growth sectors (the IS-8) - one of which being the Life Sciences Sector Plan. But what does it say?

In May, the government published its response to the Intellectual Property Office's (UK IPO) consultation on the UK's future exhaustion regime for intellectual property rights (IPR). The government has announced that the current UK+ exhaustion regime will continue in place.

The Government has published its new 10-year Industrial Strategy. It was developed in collaboration with businesses and aims to make the UK the best place in the world to invest, generate growth, and create jobs across all regions. Eight growth sectors (the IS-8) are the focus, including life sciences, digital/AI, and advanced manufacturing. Others are clean energy, defence, finance, professional and business services, and creative industries.

Operating within the UK pharmaceutical sector offers immense opportunities for innovation and public health impact. However, it also presents significant financial and regulatory challenges.

In a significant move for the UK's life sciences sector, BioNTech, renowned for its role in developing the Pfizer-BioNTech COVID-19 vaccine, has announced a £1 billion investment over the next decade.  

This paper is part of our Sustainability Insights series following the 2025 PING Conference on Sustainability - What must Pharma do now? - bringing you expert perspectives and practical takeaways from key discussions shaping the future of businesses looking to address the threats and opportunities of sustainability in the life sciences sector. Thanks to Hertfordshire Futures for their great support of PING yet again.